EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)

Kim G Smolderen, Carlos Mena-Hurtado, Zhenxiang Zhao, Wojciech Michalak, Mads Faurby, B Gabriel Smolarz iD, Mikhail N Kosiborod, Jinlin Song, Yan Chen iD, Joanna Boland, Michael G Nanna iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.70080 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Kim G Smolderen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Glucagon-Like Peptides, Hypoglycemic Agents, Obesity. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Novo Nordisk, Inc., Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real‐world settings. Materials and Methods Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016–12/31/2023) and matched 1:2 to those not on semaglutide based on a non‐parsimonious propensity‐score model. The primary outcomes included revised 3‐point MACE (rMACE‐3: myocardial infarction, stroke, and all‐cause mortality) and revised 5‐point MACE (rMACE‐5: rMACE‐3, coronary revascularisation, and hospitalisation for heart failure). Secondary outcomes included MACE‐3 and MACE‐5, defined similarly to rMACE‐3 and rMACE‐5 but replacing all‐cause mortality with cardiovascular‐related mortality. Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity‐related adverse events.

Results

A total of 9321 individuals on semaglutide 2.4 mg were matched to 18,642 individuals not on semaglutide; patient characteristics were well‐balanced between cohorts. Over a mean follow‐up of 200 days, semaglutide 2.4 mg was associated with significantly lower risks of rMACE‐5 (hazard ratio: 0.55; p < 0.001), rMACE‐3 (0.43; p < 0.001), MACE‐5 (0.65; p < 0.001), and MACE‐3 (0.58; p < 0.01). Semaglutide 2.4 mg was also associated with lower risks of all‐cause mortality, cardiovascular‐related mortality, hospitalisation for heart failure, and all exploratory outcomes.

Conclusions

In this real‐world study of US individuals with ASCVD and overweight/obesity but without diabetes, semaglutide 2.4 mg was associated with significantly reduced risk of MACEs and other obesity‐related morbidities (NCT06874751).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesGlucagon-Like PeptidesHypoglycemic AgentsObesityOverweightAgedFemaleHumansMaleMiddle AgedAtherosclerosisDiabetes Mellitus, Type 2Glucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1cardiovascular diseasecohort studyobservational studyreal‐world evidencesemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Section of Psychology, Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.
  • Novo Nordisk, Inc, Plainsboro Township, New Jersey, USA.
  • University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
  • Analysis Group, Inc, Los Angeles, California, USA.

ORCID-Profile: B Gabriel Smolarz, Yan Chen, Michael G Nanna

Förderung

  • NIA NIH HHS
  • Novo Nordisk, Inc.
  • Novo Nordisk

Zitieren

APA

Smolderen, K. G., Mena-Hurtado, C., Zhao, Z., Michalak, W., Faurby, M., Smolarz, B. G., Kosiborod, M. N., Song, J., Chen, Y., Boland, J., & Nanna, M. G. (2025). Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70080

Vancouver

Smolderen KG, Mena-Hurtado C, Zhao Z, Michalak W, Faurby M, Smolarz BG, et al. Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World). Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70080

BibTeX
@article{Smolderen2025,
  author = {Smolderen, Kim G and Mena-Hurtado, Carlos and Zhao, Zhenxiang and Michalak, Wojciech and Faurby, Mads and Smolarz, B Gabriel and Kosiborod, Mikhail N and Song, Jinlin and Chen, Yan and Boland, Joanna and Nanna, Michael G},
  title = {Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.70080}
}
Kostenlos starten →